These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30722704)

  • 21. Implications of antiviral resistance of influenza viruses.
    Monto AS
    Clin Infect Dis; 2009 Feb; 48(4):397-9. PubMed ID: 19586376
    [No Abstract]   [Full Text] [Related]  

  • 22. Recent discoveries of influenza A drug target sites to combat virus replication.
    Patel H; Kukol A
    Biochem Soc Trans; 2016 Jun; 44(3):932-6. PubMed ID: 27284062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influenza drug resistance.
    Pizzorno A; Abed Y; Boivin G
    Semin Respir Crit Care Med; 2011 Aug; 32(4):409-22. PubMed ID: 21858746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multivalent ligand presentation as a central concept to study intricate carbohydrate-protein interactions.
    Jayaraman N
    Chem Soc Rev; 2009 Dec; 38(12):3463-83. PubMed ID: 20449063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity.
    Jin J; Chen Y; Wang D; Ma L; Guo M; Zhou C; Dou J
    Arch Pharm Res; 2018 Jun; 41(6):664-676. PubMed ID: 29572682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide inhibitors against influenza virus.
    Rajik M; Yusoff K
    Antivir Chem Chemother; 2011 Mar; 21(4):151-4. PubMed ID: 21602612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity.
    Desantis J; Nannetti G; Massari S; Barreca ML; Manfroni G; Cecchetti V; Palù G; Goracci L; Loregian A; Tabarrini O
    Eur J Med Chem; 2017 Sep; 138():128-139. PubMed ID: 28666191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flavonoids in the therapy and prophylaxis of flu: a patent review.
    Costa SS; Couceiro JN; Silva IC; Malvar Ddo C; Coutinho MA; Camargo LM; Muzitano MF; Vanderlinde FA
    Expert Opin Ther Pat; 2012 Oct; 22(10):1111-21. PubMed ID: 22971104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probing the effect of quercetin 3-glucoside from Dianthus superbus L against influenza virus infection- In vitro and in silico biochemical and toxicological screening.
    Nile SH; Kim DH; Nile A; Park GS; Gansukh E; Kai G
    Food Chem Toxicol; 2020 Jan; 135():110985. PubMed ID: 31765700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlling Ligand Spacing on Surface: Polyproline-Based Fluorous Microarray as a Tool in Spatial Specificity Analysis and Inhibitor Development for Carbohydrate-Protein Interactions.
    Lin TH; Lin CH; Liu YJ; Huang CY; Lin YC; Wang SK
    ACS Appl Mater Interfaces; 2017 Dec; 9(48):41691-41699. PubMed ID: 29148699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antivirals and resistance: influenza virus.
    Ison MG
    Curr Opin Virol; 2011 Dec; 1(6):563-73. PubMed ID: 22440914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent progress and challenges in the discovery of new neuraminidase inhibitors.
    Chamni S; De-Eknamkul W
    Expert Opin Ther Pat; 2013 Apr; 23(4):409-23. PubMed ID: 23369206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bridging lectin binding sites by multivalent carbohydrates.
    Wittmann V; Pieters RJ
    Chem Soc Rev; 2013 May; 42(10):4492-503. PubMed ID: 23598793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cracking the code for H5N1-bird flu and beyond.
    Thomson RJ; Haselhorst T; Dyason JC; von Itzstein M
    Curr Drug Deliv; 2009 Aug; 6(4):343-6. PubMed ID: 19534713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro inhibition of influenza A virus infection by marine microalga-derived sulfated polysaccharide p-KG03.
    Kim M; Yim JH; Kim SY; Kim HS; Lee WG; Kim SJ; Kang PS; Lee CK
    Antiviral Res; 2012 Feb; 93(2):253-259. PubMed ID: 22197247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
    Hu Y; Musharrafieh R; Ma C; Zhang J; Smee DF; DeGrado WF; Wang J
    Antiviral Res; 2017 Apr; 140():45-54. PubMed ID: 28087313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-Pyridinyl-4(3H)-quinazolinone: a scaffold for anti-influenza A virus compounds.
    Liu S; Wang W; Jiang L; Wan S; Zhang L; Yu R; Jiang T
    Chem Biol Drug Des; 2015 Nov; 86(5):1221-5. PubMed ID: 26017319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zanamivir. A potent and selective inhibitor of influenza A and B viruses.
    Aoki FY; Hayden FG
    Clin Pharmacokinet; 1999; 36 Suppl 1():v-ix. PubMed ID: 10429834
    [No Abstract]   [Full Text] [Related]  

  • 39. Exploring Rigid and Flexible Core Trivalent Sialosides for Influenza Virus Inhibition.
    Kiran P; Bhatia S; Lauster D; Aleksić S; Fleck C; Peric N; Maison W; Liese S; Keller BG; Herrmann A; Haag R
    Chemistry; 2018 Dec; 24(72):19373-19385. PubMed ID: 30295350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of influenza virus activity by multivalent glycoarchitectures with matched sizes.
    Papp I; Sieben C; Sisson AL; Kostka J; Böttcher C; Ludwig K; Herrmann A; Haag R
    Chembiochem; 2011 Apr; 12(6):887-95. PubMed ID: 21384484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.